Tetragon Partners GP Ltd: AUTOLUS THERAPEUTICS LTD (AUTL): Quarterly 13F Position History
As of Q1 2026, Tetragon Partners GP Ltd reported 9,500,000 shares of AUTOLUS THERAPEUTICS LTD (AUTL), worth $13.1M and representing 2.6% of its 13F equity book. The position first appeared in Q2 2018 and has been disclosed across 32 13F-HR filings in Pactolio's tracked window.
- 9,500,000Shares Held (Latest Filing)
- $13.1MReported Market Value (Latest Filing)
- 2.6%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$5.8MQuarter-over-Quarter Value Change
- 12,000,000Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 32 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 9,500,000 | 0 | — | $13.1M | 2.6% | $1.4 |
| Q4 2025 | 9,500,000 | 0 | — | $18.9M | 4.0% | $2.0 |
| Q3 2025 | 9,500,000 | 0 | — | $15.5M | 2.2% | $1.6 |
| Q2 2025 | 9,500,000 | +900,000 | +10.5% | $21.7M | 3.9% | $2.3 |
| Q1 2025 | 8,600,000 | +350,000 | +4.2% | $13.3M | 4.3% | $1.6 |
| Q4 2024 | 8,250,000 | +250,000 | +3.1% | $19.4M | 6.0% | $2.4 |
| Q3 2024 | 8,000,000 | 0 | — | $29.0M | 9.3% | $3.6 |
| Q2 2024 | 8,000,000 | +474,318 | +6.3% | $27.8M | 8.6% | $3.5 |
| Q1 2024 | 7,525,682 | 474,318 | -5.9% | $48.0M | 13.2% | $6.4 |
| Q4 2023 | 8,000,000 | 4,000,000 | -33.3% | $51.5M | 13.1% | $6.4 |
| Q3 2023 | 12,000,000 | 0 | — | $28.0M | 5.1% | $2.3 |
| Q2 2023 | 12,000,000 | +2,000,000 | +20.0% | $28.6M | 3.9% | $2.4 |
| Q1 2023 | 10,000,000 | +1,700,000 | +20.5% | $18.4M | 2.5% | $1.8 |
| Q4 2022 | 8,300,000 | +5,260,619 | +173.1% | $15.8M | 2.3% | $1.9 |
| Q3 2022 | 3,039,381 | +19,968 | +0.7% | $6.5M | 0.8% | $2.1 |
| Q2 2022 | 3,019,413 | +193,476 | +6.8% | $8.5M | 0.6% | $2.8 |
| Q1 2022 | 2,825,937 | +125,937 | +4.7% | $11.8M | 0.5% | $4.2 |
| Q4 2021 | 2,700,000 | +200,000 | +8.0% | $14.0M | 0.8% | $5.2 |
| Q3 2021 | 2,500,000 | 0 | — | $16.4M | 1.0% | $6.5 |
| Q2 2021 | 2,500,000 | +64,286 | +2.6% | $16.6M | 0.9% | $6.6 |
| Q1 2021 | 2,435,714 | +285,714 | +13.3% | $14.0M | 1.0% | $5.7 |
| Q4 2020 | 2,150,000 | 0 | — | $19.2M | 1.3% | $8.9 |
| Q3 2020 | 2,150,000 | 0 | — | $25.0M | 2.5% | $11.6 |
| Q2 2020 | 2,150,000 | +167,399 | +8.4% | $34.5M | 4.6% | $16.0 |
| Q1 2020 | 1,982,601 | +682,601 | +52.5% | $11.9M | 2.1% | $6.0 |
| Q4 2019 | 1,300,000 | 0 | — | $17.2M | 2.5% | $13.2 |
| Q3 2019 | 1,300,000 | +300,000 | +30.0% | $16.1M | 2.9% | $12.4 |
| Q2 2019 | 1,000,000 | +148,369 | +17.4% | $16.1M | 2.3% | $16.1 |
| Q1 2019 | 851,631 | +51,631 | +6.5% | $26.8M | 3.3% | $31.5 |
| Q4 2018 | 800,000 | +9,850 | +1.2% | $26.3M | 4.3% | $32.8 |
| Q3 2018 | 790,150 | +765,150 | +3060.6% | $24.2M | 2.9% | $30.7 |
| Q2 2018 | 25,000 | — | — | $670.0K | 0.1% | $26.8 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Tetragon Partners GP Ltd first disclose a AUTL position in 13F-HR filings?
Tetragon Partners GP Ltd first reported AUTOLUS THERAPEUTICS LTD (AUTL) on its 13F-HR filing for the period ending 2018-06-30 (Q2 2018). The position has appeared on 32 reported quarters within Pactolio's tracked window.
What was Tetragon Partners GP Ltd's most recent quarter-over-quarter share-count change in AUTL?
Tetragon Partners GP Ltd held the same 9,500,000 shares of AUTL between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Tetragon Partners GP Ltd's cost basis in AUTL?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.